
    
      The duration of the study for each patient will include approximately 4 weeks of a screening
      phase prior to first infusion of study drug, 21-day study treatment cycles and end of
      treatment visit. The patient can continue treatment until disease progression, unacceptable
      toxicity, or the patient's refusal of further treatment.
    
  